[1]李 涛,柴培培,张毓辉,等.我国肿瘤治疗费用核算与筹资负担分析[J].卫生经济研究,2021,38(7):17-20.
　LI Tao,CHAI Pei-pei,ZHANG Yu-hui,et al.Analysis of Cost Accounting and Financing Burden of Tumor Treatment in China[J].Journal Press of Health Economics Research,2021,38(7):17-20.
点击复制

我国肿瘤治疗费用核算与筹资负担分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年7期
页码:
17-20
栏目:
成本与费用
出版日期:
2021-06-30

文章信息/Info

Title:
Analysis of Cost Accounting and Financing Burden of Tumor Treatment in China
作者:
李 涛1; 柴培培1; 张毓辉1; 万 泉1; 翟铁民1; 郭 锋1; 李 岩1; 王荣荣1; 陈春梅1; 刘国祥2
1.国家卫生健康委卫生发展研究中心，北京 100044
2.哈尔滨医科大学，黑龙江 哈尔滨150086
Author(s):
LI Tao;  CHAI Pei-pei;  ZHANG Yu-hui;  WAN Quan;  ZHAI Tie-min; GUO Feng;  LI Yan;  WANG Rong-rong;  CHEN Chun-mei;  LIU Guo-xiang
Health Development Research Center of National Health Committee, Beijing 100044, China
关键词:
肿瘤; 治疗费用; 筹资机制
Keywords:
tumor;  treatment cost;  financing mechanism
分类号:
R19
文献标志码:
A
摘要:
目的：为我国肿瘤防治政策和筹资机制调整提供数据支撑。方法：基于“卫生费用核算体系2011”，核算2018年我国肿瘤治疗费用情况。结果：2018年我国肿瘤治疗费用3 924.62亿元；服务分布上，87.53%的费用发生在住院；病种分布上，83.44%的费用用于癌症治疗，主要是肺癌、乳房恶性肿瘤、胃癌、肝癌等；机构流向上，72.53%的费用流向综合医院；年龄分布上，72.79%的费用集中在45~74岁人群；筹资来源上，公共筹资方案占62.76%，家庭卫生支出占27.48%。结论：肿瘤发病趋势将带来治疗费用的持续增长，要建立合理的筹资机制，增加筹资总量，优化资金存量，合理支出结构，以达到更好的肿瘤防治效果。
Abstract:
Objective To provide data support for the adjustment of tumor prevention and treatment policy and financing mechanism in China. Methods Based on the Health Cost Accounting System 2011, the cost of tumor treatment in China in 2018 was calculated. Results In 2018, the cost of tumor treatment in China was 392.462 billion yuan; in terms of service distribution, 87.53% of the expenses were incurred in hospitalization; in the distribution of diseases, 83.44% of the expenses were spent on cancer treatment, mainly lung cancer, breast malignant tumors, gastric cancer, liver cancer, etc.; in the flow direction of institutions, 72.53% of the expenses went to general hospitals; in terms of age distribution, 72.79% of the expenses were concentrated in people aged 45 to 74 years old. In terms of financing sources, public financing plan accounted for 62.76%, and household health expenditure accounted for 27.48%. Conclusion The trend of tumor incidence will lead to the continuous increase of treatment costs. It is necessary to establish a reasonable financing mechanism, increase the total amount of financing, optimize the stock of funds and reasonable expenditure structure in order to achieve a better effect of tumor prevention and treatment.

参考文献/References:

[1] 国家卫生健康委.健康中国行动——癌症防治实施方案（2019—2022年）[R].2019.
[2] 翟铁民，张毓辉，万泉，等.基于“卫生费用核算体系2011”的中国卫生费用核算方法学研究[J].中国卫生经济，2015，34（3）：9-11.
[3] 陈万青，郑荣寿，张思维，等.2012年中国恶性肿瘤发病和死亡分析[J].中国肿瘤，2016，25（1）：4-11.
[4] 吴炳义，董惠玲，王在翔，等.恶性肿瘤对平均预期寿命影响的生命表分析[J].现代预防医学，2015，42（23）：4328-4331.
[5] 王敏，张开金，姜丽，等.恶性肿瘤住院患者直接经济负担影响因素及医疗保障制度研究[J].中国全科医学，2010，13（12）：4115-4118.
[6] 朱波，王英，陈艳华，等.恶性肿瘤患者放化疗后医院感染分析[J].中华医院感染学杂志，2010，20（16）：2421-2422.
[7] 王庆生，陈万青.癌症防治策略的探索与分析[J].中国医学前沿杂志（电子版），2016，8（7）：13-16.
[8] 董丹丹，孙纽云，孙冬悦，等.医保基金有效使用：风险管理、国际经验与政策建议[J].中国卫生政策研究，2012，6（1）：21-27.

相似文献/References:

[1]于保荣,冯映雪,江陈庆,等.肿瘤疾病经济负担与健康保险政策研究[J].卫生经济研究,2018,(04):14.
[2]任杨玲,杨晓玮,沈 迟,等.陕西省不同年龄人群治疗费用分布研究——基于经常性卫生费用[J].卫生经济研究,2019,(02):46.
　REN Yang-ling,YANG Xiao-wei,SHEN Chi,et al.Study on the Distribution of Treatment Costs for Different Age Groups in Shaanxi Province——Based on Regular Health Costs[J].Journal Press of Health Economics Research,2019,(7):46.
[3]李 勇,王 冬,向国春,等.广东省恶性肿瘤治疗费用核算结果分析——基于“SHA2011”[J].卫生经济研究,2019,(09):25.
　LI Yong,WANG Dong,XIANG Guo-chun,et al.Analysis of Accounting Results of Treatment Costs for Malignant Tumors in Guangdong Province——Based on “SHA2011”[J].Journal Press of Health Economics Research,2019,(7):25.
[4]董 辉,汤质如,严 训,等.安徽省恶性肿瘤治疗费用分析——基于“卫生费用核算体系2011”[J].卫生经济研究,2021,38(2):58.
　DONG Hui,TANG Zhi-ru,YAN Xun,et al.Analysis on Malignant Tumor Treatment Cost in Anhui Province——Based on the SHA 2011[J].Journal Press of Health Economics Research,2021,38(7):58.
[5]陈春华,曹 勇,朱碧帆,等.2014—2018年上海市老年人治疗费用核算与分析——基于“卫生费用核算体系2011”[J].卫生经济研究,2022,39(5):27.
　CHEN Chun-hua,CAO Yong,ZHU Bi-fan,et al.Accounting and Analysis of Treatment Costs for the Elderly in Shanghai from 2014 to 2018 ——Based on "the System of Health Accounts 2011"[J].Journal Press of Health Economics Research,2022,39(7):27.
[6]王 虹,张云霞,韩 颖.县域医共体下某省基层医疗卫生机构治疗费用核算[J].卫生经济研究,2023,40(9):61.
　WANG Hong,ZHANG Yunxia,HAN Ying.Study on Treatment Costs Accounting of Primary Medical and Health Institutions under County-level Medical Community in a Certain Province[J].Journal Press of Health Economics Research,2023,40(7):61.
[7]陈荣盛,刘 平,龚亚萍,等.基于“SHA2011”的福建省女性恶性肿瘤治疗费用核算分析[J].卫生经济研究,2023,40(11):53.
　CHEN Rongsheng,LIU Ping,GONG Yaping,et al.Analysis of Treatment Costs Accounting of Female Malignant Tumors in Fujian Province based on "SHA 2011"[J].Journal Press of Health Economics Research,2023,40(7):53.
[8]郑思越,李欣雨,廖云鹏,等.辅助生殖技术治疗费用分担机制研究[J].卫生经济研究,2024,41(11):62.
　ZHENG Siyue,LI Xinyu,LIAO Yunpeng,et al.Study on the Cost Sharing Mechanism of Assisted Reproductive Technology Treatment[J].Journal Press of Health Economics Research,2024,41(7):62.
[9]刘慧玲,赵恒伯,谢志勤,等.2022年江西省罕见病治疗费用核算分析 ——基于SHA2011[J].卫生经济研究,2025,42(02):46.
　LIU Huiling,ZHAO Hengbo,XIE Zhiqin,et al.Analysis of Rare Disease Treatment Cost Accounting in Jiangxi Province in 2022 ——Based on SHA2011[J].Journal Press of Health Economics Research,2025,42(7):46.

更新日期/Last Update: 2021-06-30